🔗 Share this article WHO Issues Concern Over Critical Lack of Obesity Medications Under a tenth of individuals that would benefit from obesity jabs including Wegovy can access them, caution the global health agency as it issues its initial guidance on the medications. With more than one billion individuals worldwide currently classified as obese, it is calling for broader and more equitable access to GLP-1 medication. According to projections, over two billion will be living with obesity by 2030 unless action is taken. "Our latest guidelines recognises that excess weight is a chronic disease that can be addressed with thorough and lifelong care," stated WHO director-general Tedros Adhanom Ghebreyesus. Substantial prices, insufficient output, and distribution challenges are major obstacles to broad access to the jabs that can assist patients in reducing considerable body mass, notes the body. Skinny Jab Supply Crisis Even in the current most favorable case, the production of such drugs would only suffice for about 100 million people – less than 10% of eligible patients, according to the health organization. The guideline urges countries and companies to widen access, by measures like licensing agreements. A patent on the active ingredient – the primary component of the drug Wegovy – is scheduled to end in several nations in 2026. How Obesity Jabs Work GLP-1 drugs replicate a biological compound to delay gastric emptying, reduce hunger and increase the sense of being full so users eat less. Patients typically begin shedding pounds within a few weeks of starting on the regular doses. Evidence suggests people may see weight return within a year of stopping the treatment, when their typical appetite resume. To be overweight or obese elevates your likelihood for contracting medical conditions, such as diabetes, heart disease, brain attack, and some malignancies. Obesity affects individuals in all nations and was responsible for millions of deaths worldwide in 2024, per the WHO.
Under a tenth of individuals that would benefit from obesity jabs including Wegovy can access them, caution the global health agency as it issues its initial guidance on the medications. With more than one billion individuals worldwide currently classified as obese, it is calling for broader and more equitable access to GLP-1 medication. According to projections, over two billion will be living with obesity by 2030 unless action is taken. "Our latest guidelines recognises that excess weight is a chronic disease that can be addressed with thorough and lifelong care," stated WHO director-general Tedros Adhanom Ghebreyesus. Substantial prices, insufficient output, and distribution challenges are major obstacles to broad access to the jabs that can assist patients in reducing considerable body mass, notes the body. Skinny Jab Supply Crisis Even in the current most favorable case, the production of such drugs would only suffice for about 100 million people – less than 10% of eligible patients, according to the health organization. The guideline urges countries and companies to widen access, by measures like licensing agreements. A patent on the active ingredient – the primary component of the drug Wegovy – is scheduled to end in several nations in 2026. How Obesity Jabs Work GLP-1 drugs replicate a biological compound to delay gastric emptying, reduce hunger and increase the sense of being full so users eat less. Patients typically begin shedding pounds within a few weeks of starting on the regular doses. Evidence suggests people may see weight return within a year of stopping the treatment, when their typical appetite resume. To be overweight or obese elevates your likelihood for contracting medical conditions, such as diabetes, heart disease, brain attack, and some malignancies. Obesity affects individuals in all nations and was responsible for millions of deaths worldwide in 2024, per the WHO.